PSMA binder-2

PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) [1][2].

Product Specifications

CAS Number

[2149567-00-8]

UNSPSC

12352005

Target

PSMA

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/psma-binder-2.html

Purity

97.35

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C#CC1=CC=CC(NC(NCCCC[C@@H](C(OC(C)(C)C)=O)NC(N[C@H](C(OC(C)(C)C)=O)CCC(OC(C)(C)C)=O)=O)=O)=C1

Molecular Formula

C33H50N4O8

Molecular Weight

630.77

References & Citations

[1]Sun M, et al. Prostate-Specific Membrane Antigen (PSMA) -Targeted Radionuclide Therapies for Prostate Cancer. Curr Oncol Rep. 2021 Mar 29;23 (5) :59.|[2]Zitzmann-Kolbe S, et al., Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254) ) for the treatment of metastatic castration resistant prostate cancer (mCRPC) [J]. Cancer Research, 2024, 84 (6_Supplement) : 6033-6033.